Article Figures & Data
Figures
- Figure 1
The flow chart of Efficacy and Safety of Minocycline in Patients with Moderate to Severe Acute Ischaemic Stroke trial.
Tables
- Table 1
Assessment schedule
Screening and enrolment Treatment and follow-up Visit 1 Visit 2 Visit 3 Visit 4 Time Baseline 24±2 hours after randomisation 6±1 days after randomisation 90±7 days after randomisation Informed consent × Inclusion/exclusion criteria × Demographics × Medical history × SARS-CoV-2 infection × × × Physical examination × × × Swallowing function evaluation × × NIHSS × × × mRS × × EQ-5D × Reperfusion therapy evaluation × hs-CRP × × Routine laboratory test ×* ׆ Venous blood sample‡ × × × Cerebral haemodynamic function (single-centre) × × × Outcome event ק × ×¶ ECG × Primary diagnosis × Final diagnosis × Randomisation × Compliance × × Drug dispense/retrieve × × × AE/SAE × × × Concomitant medication × × × × *Routine blood counts, liver function, renal function, coagulation function and pregnancy test (for women of childbearing age) must be completed during screening.
†Results of routine blood counts, biochemical panels (including liver function, renal function, blood lipids, creatine kinase), glycosylated haemoglobin, homocysteine and coagulation function test should be recorded if completed in clinical.
‡Venous blood samples will be collected, followed by the separation, packaging and freezing of plasma for storage.
§The assessment of outcome events at 24±2 hours and 6±1 days after randomisation included early neurological deterioration, stroke (ischaemic stroke and haemorrhagic stroke), myocardial infarction, death, symptomatic intracranial haemorrhage, any bleeding event, antibiotics-associated diarrhoea, enteritis and constipation.
¶The assessment of outcome events at 90±7 days after randomisation included stroke (ischaemic and haemorrhagic strokes), myocardial infarction, death and any bleeding event.
AE, adverse event; EQ-5D, EuroQol-5 Dimension; hs-CRP, high-sensitivity C-reactive protein; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; SAE, serious adverse event.
Supplementary data
